{"filing":{"accession_number":"0001193805-26-001039","cik":"0001768224","ticker":"ARCT","company_name":"Arcturus Therapeutics Holdings Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"e665679_8k-arct.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_8k-arct.htm"},"events":[{"id":25663,"run_id":23288,"accession_number":"0001193805-26-001039","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Arcturus' financial results for Q2 2026 (quarter ended June 30, 2026), including revenue, R\u0026D expenses, net loss, and balance sheet metrics. The press release (Exhibit 99.1) announces quarterly financial results and provides corporate updates on pipeline progress. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.","company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26553,"accession_number":"0001193805-26-001039","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Arcturus' financial results for Q2 2026 (quarter ended June 30, 2026), including revenue, R\u0026D expenses, net loss, and balance sheet metrics. The press release (Exhibit 99.1) announces quarterly financial results and provides corporate updates on pipeline progress. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:21:12.116539+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26553,"accession_number":"0001193805-26-001039","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Arcturus' financial results for Q2 2026 (quarter ended June 30, 2026), including revenue, R\u0026D expenses, net loss, and balance sheet metrics. The press release (Exhibit 99.1) announces quarterly financial results and provides corporate updates on pipeline progress. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:21:12.116539+00:00","company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","filing_date":"2026-08-06"}]}